- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 Inhibitors: Benefit/Risk Balance
Authors
Keywords
Cardiovascular disease, Gliflozin, Kidney, SGLT2 inhibitor, Type 2 diabetes mellitus
Journal
Current Diabetes Reports
Volume 16, Issue 10, Pages -
Publisher
Springer Nature
Online
2016-08-19
DOI
10.1007/s11892-016-0789-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of diabetes drugs on the skeleton
- (2016) Christian Meier et al. BONE
- Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
- (2016) Atsushi Tanaka et al. Cardiovascular Diabetology
- Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
- (2016) Eberhard Standl et al. CIRCULATION RESEARCH
- The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus
- (2016) Maria Alba et al. CURRENT MEDICAL RESEARCH AND OPINION
- Sodium glucose cotransporter 2 inhibition in the diabetic kidney
- (2016) Aleksandra Novikov et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
- (2016) André J. Scheen DIABETES & METABOLISM
- Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
- (2016) A.J. Scheen DIABETES & METABOLISM
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
- (2016) Nikolaus Marx et al. EUROPEAN HEART JOURNAL
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis
- (2016) Xiaoyan Zhong et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The EMPA-REG study: What has it told us? A diabetologist’s perspective
- (2016) Ralph A. DeFronzo JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
- (2016) Biff F. Palmer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT2 inhibitors and heart failure — clinical implications
- (2016) Itamar Raz et al. Nature Reviews Cardiology
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
- (2015) C David Sjöström et al. Diabetes & Vascular Disease Research
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
- (2015) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
- (2015) William T. Cefalu et al. DIABETOLOGIA
- SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
- (2015) André J. Scheen Expert Opinion On Drug Safety
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
- (2015) Xiang-Yang Liu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Serum uric acid and the risk of cardiovascular and renal disease
- (2015) Claudio Borghi et al. JOURNAL OF HYPERTENSION
- SGLT2 inhibitors: their potential reduction in blood pressure
- (2015) George Maliha et al. Journal of the American Society of Hypertension
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Sodium-Glucose Cotransporter Type 2 Inhibitors in Older Adults with Type 2 Diabetes Mellitus
- (2015) Nasser Mikhail SOUTHERN MEDICAL JOURNAL
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- (2015) Wataru Ogawa et al. Journal of Diabetes Investigation
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’
- (2015) Agata Ptaszynska et al. Diabetes Therapy
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
- (2014) Suzanne Geerlings et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
- (2014) Greg L. Plosker DRUGS
- Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Greg L. Plosker DRUGS
- Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Lesley J. Scott DRUGS
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
- Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
- (2014) André J Scheen et al. Lancet Diabetes & Endocrinology
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus
- (2013) Anthony H. Barnett POSTGRADUATE MEDICINE
- Effects of Dapagliflozin on Cardiovascular Risk Factors
- (2013) Agata Ptaszynska et al. POSTGRADUATE MEDICINE
- Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
- (2013) Asres Berhan et al. BMC Endocrine Disorders
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Effects of SGLT2 inhibitors on cardiovascular outcomes
- (2012) Celine Foote et al. Diabetes & Vascular Disease Research
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
- (2011) Volker Vallon et al. Annual Review of Physiology
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started